Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells
Svenja Sydor(Universitätsklinikum Knappschaftskrankenhaus Bochum), Christian D. Fingas(Essen University Hospital), Sandra M. Swoboda(Johns Hopkins University), Guido Gerken, Ali Canbay(Universitätsklinikum Knappschaftskrankenhaus Bochum), L Wingerter(Essen University Hospital), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Andreas Paul(Essen University Hospital), Sami Jafoui(Essen University Hospital)
Cited by 10
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
|International Journal of Cancer|2010|520